Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

Future Oncology

Volumn 9, Issue 8, 2013, Pages 1083-1092

  Viola, David ^a   Cappagli, Virginia ^a   Elisei, Rossella ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

advanced medullary thyroid cancer; BMS 907351; cabozantinib; tyrosine kinase inhibitor; XL184

Indexed keywords

AXITINIB; CABOZANTINIB; ENZYME INHIBITOR; ERLOTINIB; LENVATINIB; MOTESANIB; PAZOPANIB; PLACEBO; REGORAFENIB; ROSIGLITAZONE; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; ANGIOGENESIS; APPETITE; ARTICLE; ASTHENIA; CANCER INHIBITION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; DYSPNEA; EUROPE; FATIGUE; FISTULA; HAND FOOT SYNDROME; HEART ARREST; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOXIA; INTESTINE PERFORATION; LUNG EMBOLISM; METASTASIS; MUCOSA INFLAMMATION; NONHUMAN; PANCREATITIS; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RESPIRATORY FAILURE; SEPTICEMIA; SIDE EFFECT; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR INVASION; WEIGHT REDUCTION;

ANILIDES; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; DRUG TOXICITY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES; THYROID NEOPLASMS;

EID: 84881306446     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.128     Document Type: Article

References (43)

1. De Lellis RA, Lloyd RV, Heitz PU, Eng C. WHO Classification of Tumours. In: Pathology and Genetics of Tumours of Endocrine Organs. DeLellis RA (Ed.). ARC Press, Lyon, France, 49-133 (2004).
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295, 2164-2167 (2006).
3. Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 19, 565-612 (2009).
4. Gertner ME, Kebebew E. Multiple endocrine neoplasia type 2. Curr. Treat. Options Oncol. 5, 315-325 (2004).
5. Gharib H, McConahey WM, Tiegs RD et al. Medullary thyroid carcinoma: Clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin. Proc. 67, 934-940 (1992).
6. Mulligan LM, Kwok JB, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458-460 (1993).
7. Romei C, Mariotti S, Fugazzola L et al; ItaMEN network. Multiple endocrine neoplasia type 2 syndromes (MEN 2): Results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur. J. Endocrinol. 163 (2), 301-308 (2010).
8. Elisei R, Romei C, Cosci B et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: Experience with 807 individuals at one center. J. Clin. Endocrinol. Metab. 92 (12), 4725-4729 (2007).
9. Elisei R, Cosci B, Romei C et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10 year follow-up study. J. Clin. Endocrinol. Metab. 93 (3), 682-687 (2008).
10. Mian C, Pennelli G, Barollo S et al. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: A useful tool for patient risk stratification. Eur. J. Endocrinol. 164 (6), 971-976 (2011).
11. Papotti M, Olivero M, Volante M et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr. Pathol. 11, 19-30 (2000).
12. Capp C, Wajner SM, Siqueira DR et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20 (8), 863-871 (2010).
13. Soh EY, Duh QY, Sobhi SA et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J. Clin. Endocrinol. Metab. 82, 3741-3747 (1997).
14. Moura MM, Cavaco BM, Pinto AE et al. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J. Clin. Endocrinol. Metab. 96 (5), E863-E868 (2011).
15. Boichard A, Croux L, Al Ghuzlan A et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J. Clin. Endocrinol. Metab. 97 (10), E2031-E2035 (2012).
16. Ciampi R, Mian C, Fugazzola L et al. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. Thyroid 23 (1), 50-57 (2013).
17. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab. 94, 1493-1499 (2009).
18. Droz JP, Schlumberger M, Rougier P et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: Experience at the Institut Gustave-Roussy. Tumori 76, 480-483 (1990).
19. Shimaoka K, Schoenfeld DA, DeWys WD et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56, 2155-2160 (1985).
20. Wells SA Jr, Robinson BG, Gagel RF et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind Phase III trial. J. Clin. Oncol. 30 (2), 134-141 (2012).
21. Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer. Ther. 10 (12), 2298-2308 (2011).
22. Sennino B, Ishiguro-Oonuma T, Wei Y et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2 (3), 270-287 (2012).
23. Schimmoller F, Zayzafoon M, Leland Chung LWK et al. Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone. Mol. Cancer Ther. 10 (11 Suppl. 1), Abstract A233 (2011).
24. Kurzrock R, Sherman SI, Ball DW et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J. Clin. Oncol. (19), 2660-2666 (2011).
25. Elisei R, Mueller S, Schoffski P et al. Clinical and biochemical activity in the EXAM trial, a Phase III study of cabozantinib (XL184) in patients with hereditary and non-hereditary medullary thyroid carcinoma (MTC). Eur. Thyroid J. 1, Abstract OP1 (2012).
26. Schoffski P, Elisei R, Müller S et al. An international double-blind, randomized, placebo-controlled Phase III (EXAM) of cabozantinib (XL184) in medullary thyroid cancer patients with documented RECIST progression at baseline. J. Clin. Oncol. 30 (15 Suppl.), Abstract 5508 (2012).
27. Cohen E, Elisei R, Schlumberger M et al. Clinical activity and pharmacokinetics (PK) of cabozantinib (XL184) in patients with medullary thyroid carcinoma (MTC). Ann. Oncol. 23 (Suppl. 9), Abstract 1965 (2012).
28. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92 (3), 205-216 (2000).
29. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: Results of a Phase II randomized discontinuation trial. J. Clin. Oncol. 31 (4), 412-419 (2013).
30. Buckanovich RJ, Berger R, Sella A et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a Phase II randomized discontinuation trial (RDT). J. Clin. Oncol. 29, Abstract 5008 (2011).
31. Verslype C, Cohn AL, Kelley RK et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: Results from a Phase II randomized discontinuation trial (RDT). J. Clin. Oncol. 30, Abstract 4007 (2012).
32. Winer EP, Tolaney S, Nechushtan H et al. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a Phase 2 randomized discontinuation trial (RDT). J. Clin. Oncol. 30, Abstract 535 (2012).
33. Gordon MS, Kluger HM, Shapiro G et al. Activity of cabozantinib (XL184) in metastatic melanoma: Results from a Phase II randomized discontinuation trial (RDT). J. Clin. Oncol. 30, Abstract 8531 (2012).
34. Hellerstedt BA, Edelman G, Vogelzang NJ et al. Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a Phase II randomized discontinuation trial (RDT). J. Clin. Oncol. 30, Abstract 7514 (2012).
35. De Groot J, Prados M, Urquhart T et al. A Phase 2 study of XL184 in patients with progressive glioblastoma multiforme in first or second relapse. J. Clin. Oncol. 27 (15 Suppl.), Abstract 2047 (2009).
36. Verloop H, Smit JW, Dekkers OM. Sorafenib therapy decreases the clearance of thyrotropin. Eur. J. Endocrinol. 168 (2), 163-167 (2013).
37. Abdulrahman RM, Verloop H, Hoftijzer H et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J. Clin. Endocrinol. Metab. 95 (8), 3758-3762 (2010).
38. Tamburrino A, Molinolo AA, Salerno P et al. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. Clin. Cancer Res. 18 (13), 3532-3540 (2012).
39. Jin N, Jiang T, Rosen DM et al. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin. Cancer Res. 17 (20), 6482-6489 (2011).
40. Liu D, Hou P, Liu Z et al. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res. 69 (18), 7311-7319 (2009).
41. Choueiri TK, Pal SK, McDermott DF et al. Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J. Clin. Oncol. 30 (Suppl. 5), Abstract 364 (2012).
42. Cabanillas ME, Brose MS, Ramies DA et al. Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). J. Clin. Oncol. 30, Abstract 5547 (2012).
43. Wakelee HA, Gettinger SN, Engelman JA et al. A Phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28 (15 Suppl.), Abstract 3017 (2010).